Compare

Gonadorelin vs Melanotan II

Side-by-side observational reports from PeptIQ users. This compares self-reported patterns — not clinical head-to-head trials.

Last reviewed . By the PeptIQ team.

Observational reporting only — not medical advice. Does not recommend doses, protocols, or treatments.

Gonadorelin

744 community reports

Overall experience

From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Favorable 48% · Mixed 44% · Unfavorable overall 8%

Most reported benefits

Benefits users selected when logging a favorable or mixed check-in.

Mood
-37
Focus
-85
Sleep quality
-113
Lean mass
-27
Joint comfort
-61

Most logged side effects

Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Fatigue
-121
Nausea
-5
Water retention
-148
Appetite loss
-31
Injection site reaction
-61

Self-reported dose per injection

Median bucket: 100–200 mcg · Most common: 100–200 mcg

Reports span 10–1000 mcg

10–25
9
25–50
17
50–100
20
100–200
30
200–400
24
400–600
13
600–1000
9

Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.

Common discussion topics

timing28stacking31side effects14gonadorelin27

How repeat users are trending

Among repeat reporters, 58% said they felt similar to their last entry, 40% more positive, and 18% more negative.

Overall, repeat reporters leaned more positive than their previous entry.

Median gap between entries: 14 days · Based on 164 repeat reporters

Melanotan II

1450 community reports

Overall experience

From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Favorable 64% · Mixed 18% · Unfavorable overall 18%

Most reported benefits

Benefits users selected when logging a favorable or mixed check-in.

Mood
-167
Focus
12
Sleep quality
-101
Lean mass
-48
Joint comfort
-18

Most logged side effects

Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Fatigue
-71
Nausea
-89
Water retention
-136
Appetite loss
-52
Injection site reaction
-19

Self-reported dose per injection

Median bucket: 0.4–0.6 mg · Most common: 0.4–0.6 mg

Reports span 0.05–3 mg

0.05–0.1 mg
2
0.1–0.2 mg
5
0.2–0.4 mg
14
0.4–0.6 mg
22
0.6–1 mg
11
1–2 mg
2
2–3 mg
3

Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.

Common discussion topics

timing14stacking42side effects30melanotan ii8

How repeat users are trending

Among repeat reporters, 59% said they felt similar to their last entry, 44% more positive, and 14% more negative.

Overall, repeat reporters leaned more positive than their previous entry.

Median gap between entries: 18 days · Based on 319 repeat reporters

Sources (6)

Published sources linked on the Gonadorelin and Melanotan II wiki pages.

  1. PubMed

    Gonadotropin-releasing hormone agonists and antagonists in assisted reproduction

    Al-Inany HG, Youssef MA, Aboulghar M, et al. Cochrane Database Syst Rev. 2016

    Source
    Wiki study page →
  2. PubMed

    Microglia Rank signaling regulates GnRH neuronal function and the hypothalamic-pituitary-gonadal axis

    Collado-Sole A, Borjini N, Zhai J, et al. Science (New York, N.Y.). 2026

    Source
    Wiki study page →
  3. PubMed

    LC-HRMS characterization of the skin pigmentation and sexual enhancers melanotan II and bremelanotide sold on the black market of performance and image enhancing drugs

    Mestria S, Odoardi S, Frison G, et al. Drug testing and analysis. 2021

    Source
    Wiki study page →
  4. PubMed

    Melanotan II injection resulting in systemic toxicity and rhabdomyolysis

    Nelson ME, Bryant SM, Aks SE. Clinical toxicology (Philadelphia, Pa.). 2012

    Source
    Wiki study page →